TBK1 and frontotemporal dementia: Our data suggest a total decrease of TBK1 RNA-expression in mutation carriers which corresponds to 54% and 70% of the levels in controls, in fibroblasts and brain tissue respectively, indicating a chronic reduction in expression of TBK1 starting in preclinical phases and extending to more severe FTD stages.